DYNAVAX TECHNOLOGIES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-12-29: Form 8-K; Period of report 2025-12-23; Description 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; Details 1.01.
- 2025-11-05: Form 8-K; Period of report 2025-11-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2025-10-16: Form 8-K; Period of report 2025-10-15; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2025-08-21: Form 8-K; Period of report 2025-08-21; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2025-12-29 | 8-K | 2025-12-23 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 5.02 In view of the pending Transactions, on December 23, 2025, the Company Board determined that David F. Novack would continue in his role as the Company’s President and Chief Operating Officer, and Robert Janssen, M.D would continue in his role as Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs, until the earlier of the Effective Time and the termination of the Merger Agreement. 7.01 On December 24, 2025, the Company issued a press release announcing the execution of the Merger Agreement as described above. | d82616d8k.htm |
| 2025-11-05 | 8-K | 2025-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2025, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the third quarter ended September 30, 2025. | dvax-20251105.htm |
| 2025-10-16 | 8-K | 2025-10-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 In connection with an internal realignment of various management roles and responsibilities, on October 15, 2025, the Board of Directors (the “Board”) of Dynavax Technologies Corporation (the “Company”) approved the transition of David F. Novack from his roles as the Company’s President and Chief Operating Officer to his new roles as Senior Vice President and Chief Operating Officer, effective January 1, 2026. | d40644d8k.htm |
| 2025-08-21 | 8-K | 2025-08-21 | 7.01 Regulation FD Disclosure | 7.01 On August 21, 2025, Dynavax Technologies Corporation (“Dynavax” or the “Company”) issued a press release announcing topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, the Company’s novel shingles vaccine candidate, head-to-head versus Shingrix in participants aged 50 to 69 years. | d57006d8k.htm |
| 2025-08-07 | 8-K | 2025-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2025, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the second quarter ended June 30, 2025. | dvax-20250807.htm |
| 2025-06-17 | 8-K | 2025-06-11 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 3.03 The information set forth in Item 5.03 below is incorporated by reference herein. 5.03 As described in Item 5.07 below, at the 2025 Annual Meeting of Stockholders of Dynavax Technologies Corporation (the “Company”) held on June 11, 2025, pursuant to notice duly given (the “Annual Meeting”), the stockholders of the Company approved the amendment and restatement of the Company’s Restated Certificate of Incorporation, in the form of the Restated Certificate of Incorporation (the “Restated Certificate”) included as an appendix to the definitive proxy statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on April 17, 2025 (the “Proxy Statement”), to declassify the board of directors of the Company (the “Board”) on a phased basis over a three-year period starting in 2026, thereby providing for the annual election of all directors beginning at the 2028 Annual Meeting of Stockholders of the Company, and to make certain conforming and technical changes to the Company’s certificate of incorporation. 5.07 As of April 14, 2025, the record date for the Annual Meeting, a total of 122,411,685 shares of Common Stock were outstanding and entitled to vote. | d32789d8k.htm |
| 2025-05-13 | 8-K | 2025-05-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 8, 2025, the Board of Directors of Dynavax Technologies Corporation (the “Company”) appointed Joseph Metzinger as the Company’s Vice President, Chief Accounting Officer, effective as of May 12, 2025 (the “Effective Date”). | dvax-20250508.htm |
| 2025-05-06 | 8-K | 2025-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 On May 6, 2025, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the first quarter ended March 31, 2025. | dvax-20250506.htm |
| 2025-03-13 | 8-K | 2025-03-13 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 On March 13, 2025 (the “Closing Date”), Dynavax Technologies Corporation (the “Company”) issued $225.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2030 (the “New Notes”) in connection with the consummation of the previously announced transactions contemplated by the privately negotiated exchange and subscription agreements (the “Exchange and Subscription Agreements”) with certain holders of its outstanding 2.50% Convertible Senior Notes due 2026 (the “2026 Notes”) and one new investor. 2.03 The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated into herein by reference. 3.02 The Information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. | d935304d8k.htm |
| 2025-03-06 | 8-K | 2025-03-05 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 On March 5, 2025, Dynavax Technologies Corporation (the “Company”) entered into privately negotiated exchange and subscription agreements (the “Exchange and Subscription Agreements”) with certain holders of its outstanding 2.50% Convertible Senior Notes due 2026 (the “2026 Notes”) and certain new investors, pursuant to which the Company will issue $225.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2030 (the “New Notes”). 2.03 The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated into herein by reference. 3.02 The Information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. | d932746d8k.htm |
| 2025-02-20 | 8-K | 2025-02-19 | 8.01 Other Events | 8.01 On February 19, 2025, Dynavax Technologies Corporation (the “Company”) issued a press release in response to a stockholder’s purported nomination of candidates to stand for election to the Company’s Board of Directors at the Company’s 2025 Annual Meeting of Stockholders. | d869543d8k.htm |
| 2025-02-20 | 8-K | 2025-02-20 | 2.02 Results of Operations and Financial Condition | 2.02 On February 20, 2025, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2024. | dvax-20250220.htm |
| 2025-02-14 | 8-K | 2025-02-10 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 5.02 On February 13, 2025, the Board of Directors of the Company appointed Kelly MacDonald, the Company’s Chief Financial Officer and principal financial officer, as the Company’s principal accounting officer, effective immediately. | dvax-20250210.htm |
| 2025-02-07 | 8-K | 2025-02-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 3, 2025, Justin Burgess notified Dynavax Technologies Corporation (the “Company”) that he intends to resign from the Company, including his position as the Company’s principal accounting officer, on or about March 3, 2025. | dvax-20250203.htm |
| 2025-01-29 | 8-K | 2025-01-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On January 26, 2025, the Board of Directors (the “Board”) of Dynavax Technologies Corporation (the “Company”) appointed (i) Lauren Silvernail to serve as a Class I Director, to serve until the 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) and (ii) Emilio Emini, Ph.D. to serve as a Class III Director, to serve until the 2027 Annual Meeting of Stockholders, in each case effective as of February 3, 2025, and until her or his successor is duly elected and qualified, or until her or his earlier death, resignation or removal. 8.01 The Company’s Amended and Restated Bylaws provide that the authorized number of directors shall be fixed by the Board from time to time. | d64200d8k.htm |
| 2025-01-13 | 8-K | 2025-01-13 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On January 13, 2025, Dynavax Technologies Corporation ("Dynavax" or the "Company") issued a press release announcing its preliminary unaudited fourth quarter and full year 2024 financial highlights. 7.01 The Company has posted a presentation (the “Presentation”) to its website at www.dynavax.com, in the “Events & Presentations” subsection of the “News & Events” tab. | dvax-20250113.htm |